Navigation Links
Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
Date:11/15/2010

ounts payable

$

6,350,030

$

5,012,157Advances from customers - related parties13,045,7494,426,751Wages and benefits payable808,2281,484,852Short-term debt - related party8,958,000-Income taxes payable570,185-Contractor deposits204,451183,395Contractor payables35,554,58418,513,216Other payables 1,164,6771,151,551Other payables - related parties15,630,6253,326,110Total current liabilities82,286,52934,098,032NON-CURRENT LIABILITIESDeferred income11,470,05011,236,501Total non current liabilities11,470,05011,236,501Total liabilities93,756,57945,334,533EQUITY:Shareholders' equity of the Company:Common stock, $0.001 par value, 250,000,000 shares authorized,
71,333,586 issued and outstanding, respectively71,33471,334Paid-in-capital18,271,51818,042,189Statutory reserves16,465,14413,217,217Retained earnings128,490,119126,370,263Accumulated other comprehensive income 21,394,86418,262,123Total shareholders' equity of the Company184,692,979175,963,126Noncontrolling interest10,649,2029,812,049Total equity195,342,181185,775,175Total liabilities and equity

$

289,098,760

$

231,109,708TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009 (UNAUDITED)Nine months ended September 30,20102009CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$

5,973,772

$

22,169,036Adjustments to reconcile net income to cash provided by (used in) operating activities:Bad debt expense88,205(902,297)Depreciation1,172,5971,662,206Amortization252,075291,418Interest expense117,165(9,357)Gain on sale of assets(43,377)(14,846)Rental expense borne by a related party246,623-(Increase) decrease in assets:Accounts receivable, trade - related parties4,742,77210,678,476Other receivables(237,041)(121,058)Other receivables - related parties (92,265)(1,306,527)Inventories166,3372,801,809Employee advances3,579(80,873)Prepaid expense 236,536(336,620)Increa
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Yongye Biotechnology International Retains CCG Investor Relations
8. ThirdBiotech Announces Kemeta as Newest Sponsor
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, LLC ... with University College Hospital (UCH) Ibadan Board ... project to finance, design, construct, and operate and maintain ... Nigeria . Under the first of the 4-phase ... documents and funding applications. UCH Ibadan intends to finance ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Adult Cough Products Using ... Technologies, CHESTER, N.J. and SALT LAKE CITY, Sept. ... and Lipocine Inc., a,privately- held, leading drug delivery company ... drug delivery and,therapeutics needs, today announced that they have ...
... Company Enters Into License, Commercialization and Supply Agreement, Company to Host Conference ... ... 2007, LEXINGTON, Mass., Sept. 19 ... AGN ), through its acquisition of Esprit Pharma, has obtained the,United States ...
... Kleiner Perkins ... Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 million ...
Cached Biology Technology:Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 2Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 3Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... of Medicine has helped confirm the reliability of a ... the long-promised era of personalized medicine based on each ... the five sites that helped determine that the genetic ... developing cirrhosis from chronic hepatitis C infection. That means ...
... has shown that opening windows and doors provided ventilation ... and 18 times that of rooms with windows and ... Escombe from Imperial College London, compared the airflow in ... rooms, TB wards, respiratory wards, general medical wards, outpatient ...
... lupus, is a complex autoimmune disease marked by ... among other symptoms. Some studies have described a ... psychosis, and a protein autoantibody associated with the ... To investigate how an autoantibody could stimulate behavioral ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: